Eli Lilly & Co. (LLY)

111.46
NYSE : Health Technology
Prev Close 111.01
Day Low/High 110.00 / 112.44
52 Wk Low/High 103.66 / 132.13
Avg Volume 3.92M
Exchange NYSE
Shares Outstanding 965.43M
Market Cap 107.17B
EPS 3.10
P/E Ratio 26.37
Div & Yield 2.58 (2.15%)

Latest News

Lilly Announces Superiority Of Taltz® (ixekizumab) Versus TREMFYA® (guselkumab) In Delivering Total Skin Clearance At Week 12 In Topline Results From Head-to-Head (IXORA-R) Trial In People Living With Moderate To Severe Plaque Psoriasis

Lilly Announces Superiority Of Taltz® (ixekizumab) Versus TREMFYA® (guselkumab) In Delivering Total Skin Clearance At Week 12 In Topline Results From Head-to-Head (IXORA-R) Trial In People Living With Moderate To Severe Plaque Psoriasis

- IXORA-R is the first Phase 4 head-to-head study comparing efficacy between an IL-17A inhibitor and an IL-23/p19 inhibitor using PASI 100 as the primary endpoint -

Weekly Roundup

We are staying the course, using bouts of panic to buy up the stocks of high-quality companies on discounts.

U.S. Court Of Appeals Rules In Favor Of Lilly In Alimta Alternate Salt Form Patent Lawsuit

U.S. Court Of Appeals Rules In Favor Of Lilly In Alimta Alternate Salt Form Patent Lawsuit

INDIANAPOLIS, Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.

Lilly Announces Positive Results For Emgality™ (galcanezumab) From The CONQUER Study In Patients Who Failed Previous Migraine Preventive Treatments

Lilly Announces Positive Results For Emgality™ (galcanezumab) From The CONQUER Study In Patients Who Failed Previous Migraine Preventive Treatments

Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments 1 TORONTO, Aug.

Lilly, Evidation Health And Apple Study Shows Personal Digital Devices May Help In The Identification Of Mild Cognitive Impairment And Mild Alzheimer's Disease Dementia

Lilly, Evidation Health And Apple Study Shows Personal Digital Devices May Help In The Identification Of Mild Cognitive Impairment And Mild Alzheimer's Disease Dementia

INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc.

Lilly Announces Leadership Changes In Corporate Business Development, Oncology R&D, And Managed Healthcare Services

Lilly Announces Leadership Changes In Corporate Business Development, Oncology R&D, And Managed Healthcare Services

INDIANAPOLIS, Aug. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations.

Lilly Announces Positive Results For Emgality® (galcanezumab-gnlm) From The CONQUER Study In Patients Who Failed Previous Migraine Preventive Treatments

Lilly Announces Positive Results For Emgality® (galcanezumab-gnlm) From The CONQUER Study In Patients Who Failed Previous Migraine Preventive Treatments

-Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1)

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Eli Lilly Tops Q2 Profit Forecast, Lifts 2019 Guidance, as Trulicity Sales Surge

Eli Lilly Tops Q2 Profit Forecast, Lifts 2019 Guidance, as Trulicity Sales Surge

Eli Lilly posted stronger-than-expected second quarter earnings Tuesday, and boosted its full-year profit forecast, thanks in part to a surge in sales of its key diabetes treatment.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

Capital One, Apple, AMD, Beyond Meat, Federal Reserve - 5 Things You Must Know

U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.

Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance

- Revenue in the second quarter of 2019 grew 1 percent, driven by 6 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43 percent of total revenue.

Lilly's Verzenio® (abemaciclib) Significantly Extended Life In Women With HR , HER2- Advanced Breast Cancer In MONARCH 2

Lilly's Verzenio® (abemaciclib) Significantly Extended Life In Women With HR , HER2- Advanced Breast Cancer In MONARCH 2

Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Don't Trade, Invest: Cramer's 'Mad Money' Recap (Monday 7/15/19)

Jim Cramer says don't trade earnings season, invest in it -- and invest the time needed to be a smart, successful investor.

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Eli Lily, DuPont: 'Mad Money' Lightning Round

Jim Cramer weighs in on Bristol-Myers Squibb, Eli Lily, DuPont, Marvell Technology, General Motors, Kraft Heinz, Maxar Technologies, and more.

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

Lilly Presents New Findings On Stigma Faced By People With Migraine Based On Interim Results From The OVERCOME Observational Study

-Data from OVERCOME shed new light on migraine stigma by examining attitudes through the eyes of people who have not been diagnosed with migraine[1]

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

Lilly's OVERCOME Observational Study Reveals Inconsistent And Sub-Optimal Treatment Landscape For Migraine

-Data from OVERCOME showed that inconsistent care patterns, including high use of emergency department/urgent care settings, may be contributing to misdiagnosis, sub-optimal treatment and increased healthcare utilization(1)

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

AHS 2019: Post-Hoc Analyses Of Phase 3 Pivotal Studies Of Emgality® (galcanezumab-gnlm) Show Improvements In Daily Functioning And Reductions In Disability In Patients With Chronic And Episodic Migraine

-Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue(1)

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Lilly Announces Changes In Senior Leadership

Lilly Announces Changes In Senior Leadership

Mike Harrington, senior vice president and general counsel, to retire at year end

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

New England Journal Of Medicine Publishes Positive Phase 3 Data For Emgality® (galcanezumab-gnlm) In Episodic Cluster Headache

INDIANAPOLIS, July 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality ® (galcanezumab-gnlm) for the treatment of episodic cluster...

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

Lilly Announces Upcoming Presentation Of New Data Indicating Rise In Opioid Use For Migraine Treatment

-Findings showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease, up from 16 percent in 2009(1,2)

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

Lilly Confirms Date And Conference Call For Second-Quarter 2019 Financial Results Announcement

INDIANAPOLIS, July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

TheStreet Quant Rating: C+ (Hold)